GlassScriptPhysician profile
Vinh Duc Luu
NPI 1194715607
$3,186.57
in general payments reported to CMS, 2019-2025
20 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $251 · 2021: $305 · 2022: $795 · 2023: $201 · 2024: $519 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $876.76 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $386.94 | 2020-2025 | |
| Abbott Laboratories | $320.00 | 2019 | |
| Novo Nordisk INC | $307.31 | 2024-2025 | Wegovy |
| Philips North America LLC | $187.33 | 2022-2025 | (5091) Amb Mon & Diag Und, Diagnostic Ecg Service, (Cm9) Amb Mon & Diag Und |
| Inspire Medical Systems, INC. | $176.44 | 2022 | |
| Boston Scientific Corporation | $129.38 | 2022-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $121.83 | 2022 | |
| Cvrx, INC. | $118.80 | 2020 | |
| Sanofi-Aventis U.S. LLC | $114.80 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.78 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.17 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $58.75 | 2024-2025 | Verquvo |
| Pfizer INC. | $53.99 | 2022-2023 | |
| Amgen INC. | $47.46 | 2024 | Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $38.11 | 2020 | |
| Abiomed | $35.28 | 2024 | Impella |
| Esperion Therapeutics, INC. | $27.42 | 2025 | Nexletol |
| Cardiva Medical, INC. | $18.18 | 2019 | |
| Lilly USA, LLC | $13.84 | 2024 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinh Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.